CNS Drugs

, Volume 19, Issue 3, pp 239–252 | Cite as

US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis

Review of Adverse Effect Profiles
Review Article

Abstract

Several disease-modifying agents (DMAs) are approved for the treatment of multiple sclerosis, including three interferon (IFN)-β products, glatiramer acetate and mitoxantrone. This article reviews the adverse event profiles of these DMAs based on the pivotal phase III trials, and provides practical guidelines for managing adverse effects. In general, the most common adverse events associated with IFNβ therapy are flu-like symptoms, including fever, chills and myalgias, and headache. The flu-like symptoms typically resolve within 24 hours and may be mitigated by over-the-counter anti-inflammatory agents. Adverse events related to glatiramer acetate therapy include injection-site reactions and a systemic reaction consisting of flushing, chest tightness, palpitation, anxiety or dyspnoea. The systemic reaction is transient (30 seconds to 30 minutes) and self-limited. Mitoxantrone may cause nausea, vomiting, alopecia, amenorrhoea and myelosuppression; isolated cases of acute leukaemia and dose-related cardiotoxicity have been reported in the literature. Longer-term tolerability data on mitoxantrone as a treatment for multiple sclerosis are needed. It is important for physicians to counsel patients on DMA-related adverse effects, most of which are transient and of mild-to-moderate severity. Various strategies that can be employed to prevent or manage these adverse effects and lessen their impact on the patient are discussed.

References

  1. 1.
    The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61CrossRefGoogle Scholar
  2. 2.
    Johnson KP, Brooks BR, Cohen JA, et al., and the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268–76PubMedCrossRefGoogle Scholar
  3. 3.
    Jacobs LD, Cookfair DL, Rudick RA, et al., and the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–94PubMedCrossRefGoogle Scholar
  4. 4.
    PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–504CrossRefGoogle Scholar
  5. 5.
    Härtung H-P, Gonsette R, König N, et al., and the Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018–25PubMedCrossRefGoogle Scholar
  6. 6.
    Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis. Arch Intern Med 2002; 162: 2161–9PubMedCrossRefGoogle Scholar
  7. 7.
    European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–7CrossRefGoogle Scholar
  8. 8.
    The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–85CrossRefGoogle Scholar
  9. 9.
    Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus congress. Neurology 1996; 46: 12–8PubMedCrossRefGoogle Scholar
  10. 10.
    Jacobs LD, Beck RW, Simon JH, et al. and the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898–904PubMedCrossRefGoogle Scholar
  11. 11.
    Clanet M, Radue EW, Kappos L, et al., and the European IFNβ-1a (Avonex) Dose-Comparison Study Investigators. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002; 59: 1507–17PubMedCrossRefGoogle Scholar
  12. 12.
    Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679–87PubMedCrossRefGoogle Scholar
  13. 13.
    SPECTRIMS (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496–504CrossRefGoogle Scholar
  14. 14.
    Tremlett H, Porciuncula J, Yoshida E, et al. Post-marketing surveillance: liver test abnormalities during treatment with interferon b-1a (sc), -1a (im) and -1b (sc) in clinical practice. Neurology 2003; 60Suppl. 1: A55Google Scholar
  15. 15.
    Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-β-1a: incidence and clinical significance. Drug Saf 2003; 26: 815–27PubMedCrossRefGoogle Scholar
  16. 16.
    Tremlete HL, Yoshida EM, Oger J. Liver injury associated with the B interferons for MS: a comparison between the three products. Neurology 2004; 62: 628–31CrossRefGoogle Scholar
  17. 17.
    Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001; 56: 1416PubMedCrossRefGoogle Scholar
  18. 18.
    Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001; 57: 2153Google Scholar
  19. 19.
    Durelli L, Bongioanni MR, Ferrero B, et al. Interferon treatment for multiple sclerosis: autoimmune complication may be lethal. Neurology 1998; 50: 570–1PubMedCrossRefGoogle Scholar
  20. 20.
    Duchini A. Autoimmune hepatitis and interferon-beta 1a for multiple sclerosis. AM J Gastroenterol 2002; 97: 767–78PubMedCrossRefGoogle Scholar
  21. 21.
    Panitch H, Goodin DS, Francis G, et al., for the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496–506PubMedCrossRefGoogle Scholar
  22. 22.
    Durelli L, Verdun E, Barbero P, et al., and the Independent Comparison of Interferon (INCOMIN) Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453–60PubMedCrossRefGoogle Scholar
  23. 23.
    Betaseron® [package insert]. Montville (NJ): Berlex Laboratories, 2003Google Scholar
  24. 24.
    Rebif® [package insert]. Randolph (MA): Serono, Inc., 2003Google Scholar
  25. 25.
    Avonex® [package insert]. Cambridge (MA): Biogen Inc., 2003Google Scholar
  26. 26.
    The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628–36CrossRefGoogle Scholar
  27. 27.
    Herndon RM, Jacobs LD, Coats ME, et al. Results of an ongoing, open-1abel, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care 1999; 2: 1–6Google Scholar
  28. 28.
    Pachner AR. Anti-IFNβ antibodies in IFNβ treated MS patients. Neurology 2003; 61: S1–5CrossRefGoogle Scholar
  29. 29.
    Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsingremitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003; 74: 1689–92PubMedCrossRefGoogle Scholar
  30. 30.
    Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003; 24: 361–4PubMedCrossRefGoogle Scholar
  31. 31.
    Drago F, Brusati C, Mancardi G, et al. Localized lipoatrophy after glatiramer acetate injection in patients with remittin-grelapsing multiple sclerosis. Arch Dermatol 1999; 135:1277–8PubMedCrossRefGoogle Scholar
  32. 32.
    Mancardi GL, Murialdo A, Drago F, et al. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol 2000; 247: 220–1PubMedCrossRefGoogle Scholar
  33. 33.
    Hwang L, Orengo I. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutis 2001; 68: 287–8PubMedGoogle Scholar
  34. 34.
    Gonsette RE. Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1996; 1: 329–32PubMedGoogle Scholar
  35. 35.
    Wiseman LR, Spencer CM. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997; 10(6): 473–85PubMedCrossRefGoogle Scholar
  36. 36.
    Faulds D, Balfour JA, Chrisp P, et al. Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 41(3): 400–49PubMedCrossRefGoogle Scholar
  37. 37.
    Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153–9PubMedCrossRefGoogle Scholar
  38. 38.
    Vicari AM, Ciceri F, Folli F, et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998; 12: 441–2PubMedCrossRefGoogle Scholar
  39. 39.
    Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002; 59: 954–5PubMedCrossRefGoogle Scholar
  40. 40.
    Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441–5PubMedCrossRefGoogle Scholar
  41. 41.
    Cattaneo C, Almici C, Borlenghi E, et al. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 2003; 17: 985–6PubMedCrossRefGoogle Scholar
  42. 42.
    Heesen C, Bruegmann M, Gbdamosi J, et al. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler 2003; 9: 213–4PubMedCrossRefGoogle Scholar
  43. 43.
    Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441–5PubMedCrossRefGoogle Scholar
  44. 44.
    Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002; 59: 954–5PubMedCrossRefGoogle Scholar
  45. 45.
    Brassat D, Recher C, Huguet FR, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2003; 60: 1400Google Scholar
  46. 46.
    Gbadamosi J, Münchau A, Weiller C, et al. Severe heart failure in a young multiple sclerosis patient. J Neurol 2003; 250: 241–2PubMedCrossRefGoogle Scholar
  47. 47.
    Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622–7PubMedCrossRefGoogle Scholar
  48. 48.
    Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002; 8: 227–36PubMedCrossRefGoogle Scholar
  49. 49.
    Bayas A, Rieckmann P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Safety 2000; 22(2): 149–59PubMedCrossRefGoogle Scholar
  50. 50.
    Edgar CM, Bruenet DG, Fenton P, et al. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci. 2004; 31: 58–63PubMedGoogle Scholar
  51. 51.
    Munschauer III FE, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997; 19(5): 883–93PubMedCrossRefGoogle Scholar
  52. 52.
    Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002; 58Suppl. 4: S10–22PubMedCrossRefGoogle Scholar
  53. 53.
    Rio J, Nos C, Marzo ME, et al. Low-dose steroids reduce flulike symptoms at the initiation of IFNβ-1b in relapsing-remitting MS. Neurology 1998; 50: 1910–2PubMedCrossRefGoogle Scholar
  54. 54.
    Novantrone® [package insert]. Seattle (WA): Immunex Corporation, 2003Google Scholar
  55. 55.
    Aikens JE, Fischer JS, Namey M, et al. A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis. J Behav Med 1997; 20(5): 433–45PubMedCrossRefGoogle Scholar
  56. 56.
    Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54: 531–3PubMedCrossRefGoogle Scholar
  57. 57.
    Copaxone® [package insert]. Kansas City (MO): Aventis Pharmaceuticals Inc., 2003Google Scholar
  58. 58.
    Korczyn AD, Nisipeanu P. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. J Neurol 1996; 243Suppl. 1: S23–6PubMedCrossRefGoogle Scholar
  59. 59.
    Avasarala JR, Cross, AH, et al. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003; 9: 59–62PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Pennsylvania HospitalPhiladelphiaUSA

Personalised recommendations